Cargando…

The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator

Dopamine (3-hydroxytyramine) is a well-known catecholamine neurotransmitter involved in multiple physiological functions including movement control. Here we report that the major extracellular metabolite of dopamine, 3-methoxytyramine (3-MT), can induce behavioral effects in a dopamine-independent m...

Descripción completa

Detalles Bibliográficos
Autores principales: Sotnikova, Tatyana D., Beaulieu, Jean-Martin, Espinoza, Stefano, Masri, Bernard, Zhang, Xiaodong, Salahpour, Ali, Barak, Larry S., Caron, Marc G., Gainetdinov, Raul R.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956650/
https://www.ncbi.nlm.nih.gov/pubmed/20976142
http://dx.doi.org/10.1371/journal.pone.0013452
_version_ 1782188168149204992
author Sotnikova, Tatyana D.
Beaulieu, Jean-Martin
Espinoza, Stefano
Masri, Bernard
Zhang, Xiaodong
Salahpour, Ali
Barak, Larry S.
Caron, Marc G.
Gainetdinov, Raul R.
author_facet Sotnikova, Tatyana D.
Beaulieu, Jean-Martin
Espinoza, Stefano
Masri, Bernard
Zhang, Xiaodong
Salahpour, Ali
Barak, Larry S.
Caron, Marc G.
Gainetdinov, Raul R.
author_sort Sotnikova, Tatyana D.
collection PubMed
description Dopamine (3-hydroxytyramine) is a well-known catecholamine neurotransmitter involved in multiple physiological functions including movement control. Here we report that the major extracellular metabolite of dopamine, 3-methoxytyramine (3-MT), can induce behavioral effects in a dopamine-independent manner and these effects are partially mediated by the trace amine associated receptor 1 (TAAR1). Unbiased in vivo screening of putative trace amine receptor ligands for potential effects on the movement control revealed that 3-MT infused in the brain is able to induce a complex set of abnormal involuntary movements in mice acutely depleted of dopamine. In normal mice, the central administration of 3-MT caused a temporary mild hyperactivity with a concomitant set of abnormal movements. Furthermore, 3-MT induced significant ERK and CREB phosphorylation in the mouse striatum, signaling events generally related to PKA-mediated cAMP accumulation. In mice lacking TAAR1, both behavioral and signaling effects of 3-MT were partially attenuated, consistent with the ability of 3-MT to activate TAAR1 receptors and cause cAMP accumulation as well as ERK and CREB phosphorylation in cellular assays. Thus, 3-MT is not just an inactive metabolite of DA, but a novel neuromodulator that in certain situations may be involved in movement control. Further characterization of the physiological functions mediated by 3-MT may advance understanding of the pathophysiology and pharmacology of brain disorders involving abnormal dopaminergic transmission, such as Parkinson's disease, dyskinesia and schizophrenia.
format Text
id pubmed-2956650
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-29566502010-10-25 The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator Sotnikova, Tatyana D. Beaulieu, Jean-Martin Espinoza, Stefano Masri, Bernard Zhang, Xiaodong Salahpour, Ali Barak, Larry S. Caron, Marc G. Gainetdinov, Raul R. PLoS One Research Article Dopamine (3-hydroxytyramine) is a well-known catecholamine neurotransmitter involved in multiple physiological functions including movement control. Here we report that the major extracellular metabolite of dopamine, 3-methoxytyramine (3-MT), can induce behavioral effects in a dopamine-independent manner and these effects are partially mediated by the trace amine associated receptor 1 (TAAR1). Unbiased in vivo screening of putative trace amine receptor ligands for potential effects on the movement control revealed that 3-MT infused in the brain is able to induce a complex set of abnormal involuntary movements in mice acutely depleted of dopamine. In normal mice, the central administration of 3-MT caused a temporary mild hyperactivity with a concomitant set of abnormal movements. Furthermore, 3-MT induced significant ERK and CREB phosphorylation in the mouse striatum, signaling events generally related to PKA-mediated cAMP accumulation. In mice lacking TAAR1, both behavioral and signaling effects of 3-MT were partially attenuated, consistent with the ability of 3-MT to activate TAAR1 receptors and cause cAMP accumulation as well as ERK and CREB phosphorylation in cellular assays. Thus, 3-MT is not just an inactive metabolite of DA, but a novel neuromodulator that in certain situations may be involved in movement control. Further characterization of the physiological functions mediated by 3-MT may advance understanding of the pathophysiology and pharmacology of brain disorders involving abnormal dopaminergic transmission, such as Parkinson's disease, dyskinesia and schizophrenia. Public Library of Science 2010-10-18 /pmc/articles/PMC2956650/ /pubmed/20976142 http://dx.doi.org/10.1371/journal.pone.0013452 Text en Sotnikova et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Sotnikova, Tatyana D.
Beaulieu, Jean-Martin
Espinoza, Stefano
Masri, Bernard
Zhang, Xiaodong
Salahpour, Ali
Barak, Larry S.
Caron, Marc G.
Gainetdinov, Raul R.
The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator
title The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator
title_full The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator
title_fullStr The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator
title_full_unstemmed The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator
title_short The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator
title_sort dopamine metabolite 3-methoxytyramine is a neuromodulator
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956650/
https://www.ncbi.nlm.nih.gov/pubmed/20976142
http://dx.doi.org/10.1371/journal.pone.0013452
work_keys_str_mv AT sotnikovatatyanad thedopaminemetabolite3methoxytyramineisaneuromodulator
AT beaulieujeanmartin thedopaminemetabolite3methoxytyramineisaneuromodulator
AT espinozastefano thedopaminemetabolite3methoxytyramineisaneuromodulator
AT masribernard thedopaminemetabolite3methoxytyramineisaneuromodulator
AT zhangxiaodong thedopaminemetabolite3methoxytyramineisaneuromodulator
AT salahpourali thedopaminemetabolite3methoxytyramineisaneuromodulator
AT baraklarrys thedopaminemetabolite3methoxytyramineisaneuromodulator
AT caronmarcg thedopaminemetabolite3methoxytyramineisaneuromodulator
AT gainetdinovraulr thedopaminemetabolite3methoxytyramineisaneuromodulator
AT sotnikovatatyanad dopaminemetabolite3methoxytyramineisaneuromodulator
AT beaulieujeanmartin dopaminemetabolite3methoxytyramineisaneuromodulator
AT espinozastefano dopaminemetabolite3methoxytyramineisaneuromodulator
AT masribernard dopaminemetabolite3methoxytyramineisaneuromodulator
AT zhangxiaodong dopaminemetabolite3methoxytyramineisaneuromodulator
AT salahpourali dopaminemetabolite3methoxytyramineisaneuromodulator
AT baraklarrys dopaminemetabolite3methoxytyramineisaneuromodulator
AT caronmarcg dopaminemetabolite3methoxytyramineisaneuromodulator
AT gainetdinovraulr dopaminemetabolite3methoxytyramineisaneuromodulator